Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TreAtment Response and Omic-Markers in Triple-Negative Breast CAncer Patients Receiving Standard of Care Chemotherapy (TARMAC)

NCT06291064 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT06291064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06291064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TreAtment Response and Omic-Markers in Triple-Negative Breast CAncer Patients Receiving Standard of Care Chemotherapy (TARMAC)
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Recruiting
Start date
March 18, 2025
Completion date
June 30, 2032
Enrollment
85 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer